Wockhardt Ltd. benchmarking: Performance to industry peers

Financial

	Wockhardt	Gland Pharma	Pfizer
Operational Metrics
Pharmaceuticals
Domestic Sales Growth - YoY	10.6 %	n/a	5.2 %
R&D as a % of Total Sales	4.4 %	5.4 %	n/a
Financials
5 yr Average ROE	4.06 %	12.02 %	19.03 %
5yr average Equity Multiplier	2.02	1.15	1.25
5yr Average Asset Turnover Ratio	0.39	0.51	0.6
5yr Avg Net Profit Margin	-4.28 %	20.79 %	26.04 %
Price to Book	5.17	2.95	5.15
P/E	119.85	33.25	25.35
5yr Avg Cash Conversion Cycle	-94.15 Days	69.81 Days	21.86 Days
Inventory Days	61.29 Days	118.26 Days	49.93 Days
Days Receivable	60.36 Days	99.92 Days	29.1 Days
Days Payable	251.45 Days	107.43 Days	77.28 Days
5yr Average Interest Coverage Ratio	-0.43	183.05	185.18
5yr Avg ROCE	-0.28 %	16.55 %	23.84 %
5yr Avg Operating Profit Margin	5.03 %	29.26 %	31.72 %
5 yr average Debt to Equity	0.56	0.01	0.0
5yr CAGR Net Profit	n/a	-6.87 %	76.68 %
5yr Average Return on Assets	-1.79 %	10.65 %	15.25 %
Shareholdings
Promoter Holding	49.08 %	51.83 %	63.92 %
Share Pledged by Promoters	18.82 %	0.0	0.0
Change in Promoter Holding (3 Yrs)	-10.23 %	-6.03 %	0.0
Change in Mutual Fund Holding (3 Yrs)	8.12 %	11.53 %	5.56 %

	Wockhardt	Gland Pharma	Pfizer
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Injectables 0 Pharmaceutical 0	Product Wise Break-Up Pharmaceutical 0 Injectables 0 Others 100	Product Wise Break-Up Pharmaceutical 100.0 Injectables 0
Location Wise Break-Up	Location Wise Break-Up Rest of the World 36.17 India 19.79 Europe 0 USA 0 Canada, Australia & New Zealand 0 Australia 0 Canada 0 Others 44.04	Location Wise Break-Up Australia 0 Canada, Australia & New Zealand 2.44 Europe 5.03 Canada 0 India 6.31 Rest of the World 0 USA 70.31 Others 15.91	Location Wise Break-Up Australia 0 Canada, Australia & New Zealand 0 Europe 0 Canada 0 India 95.0 Rest of the World 5.0 USA 0
Asset Break-Up	Asset Break-Up Others 100	-	-